Journal of Vascular and Interventional Radiology
Volume 20, Issue 7 , Pages 879-887, July 2009

MR Imaging–guided Percutaneous Sclerotherapy of Peripheral Venous Malformations with a Clinical 1.5-T Unit: A Pilot Study

  • Gustav Andreisek, MD

      Affiliations

    • Institute for Diagnostic Radiology, University Hospital Zuerich, Raemistrasse 100, CH- 8091 Zürich, Switzerland
    • Corresponding Author InformationAddress correspondence to G.A.
  • ,
  • Daniel Nanz, PhD

      Affiliations

    • Department of Medical Radiology, University Hospital Zuerich, Raemistrasse 100, CH- 8091 Zürich, Switzerland
  • ,
  • Dominik Weishaupt, MD

      Affiliations

    • Division of Radiology, Triemli Hospital, Zürich, Switzerland
  • ,
  • Thomas Pfammatter, MD

      Affiliations

    • Institute for Diagnostic Radiology, University Hospital Zuerich, Raemistrasse 100, CH- 8091 Zürich, Switzerland

Received 29 November 2007; received in revised form 22 February 2009; accepted 9 March 2009. published online 28 May 2009.

Purpose

To evaluate the feasibility of magnetic resonance (MR) imaging–guided percutaneous sclerotherapy of venous malformations (VMs) by using a clinical 1.5-T MR unit and the safety and therapeutic outcome of the performed procedures.

Materials and Methods

This is a prospective pilot study with ethical approval and written informed patient consent. Ten MR imaging–guided percutaneous sclerotherapy treatments were performed in 10 patients (one male and nine female patients; age range, 16–47 years; mean age, 30.3 years) with a VM in the foot and/or ankle (n = 5), calf (n = 2), thigh and/or knee (n = 2), and elbow (n = 1). MR imaging was used for needle insertion guidance and real-time monitoring of the injection process by using three-dimensional fast spoiled gradient-echo MR sequences (repetition time msec/echo time msec = 3.7–5.2/1.1–1.6, flip angle = 35°) and meglumine gadoterate/ethanol solutions as the sclerosing agent. The technical success (ie, absence of technical problems, number of needle position corrections) was systematically evaluated along with safety aspects (ie, absence of complications) and the therapeutic outcome (eg, VM volume decrease, relief of symptoms) during a 1-year follow-up period.

Results

MR imaging–guided sclerotherapy was technically successful in all patients. A mean of 2.5 ± 1.85 (range, 1–6) needle position corrections were needed for correct needle placement. The distribution of the sclerosing agent (mean amount, 10.5 mL; range, 0.8–33.0 mL) was clearly visible with real-time MR monitoring. One patient developed a compartment syndrome, which was managed with surgery. No other complications were observed. VM volumes significantly decreased by 53% (range, 24%–86%; P = .02) 12 weeks after therapy. Nine of the 10 patients (90%) noted an improvement of symptoms.

Conclusions

In this limited preliminary series, 1.5-T MR imaging–guided percutaneous sclerotherapy for the treatment of VMs was feasible with a high degree of technical success, was relatively safe, and had a good therapeutic outcome after 1 year.

Abbreviations: FSE, fast spin echo, GRE, gradient echo, MIP, maximum intensity projection, 3D, three-dimensional, VM, vascular malformation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 None of the authors have identified a conflict of interest.

PII: S1051-0443(09)00332-7

doi:10.1016/j.jvir.2009.03.034

Journal of Vascular and Interventional Radiology
Volume 20, Issue 7 , Pages 879-887, July 2009